Sunitinib: from rational design to clinical efficacy.

By L. Chow, S. Eckhardt. Journal of Clinical Oncology, 2007

866 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/ea327a6bafdd7ee6533e618cd5f35b0aaaff5ca6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. D. McDonald
2. G. Wilding

Citations in the corpus

• Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma (2009, background): “Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor of vascular endothelial and platelet-derived growth factor receptors.(1) A high response rate observed in the second-line treatment setting(2,3) led to the design and conduct of a randomized phase III trial of sunitinib comp”
• Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma (2010, neutral): “VEGFR and PDGFR activity [351].”
• Mechanisms of adverse effects of anti-VEGF therapy for cancer (2007, background): “Clinical or laboratory evidence of hypothyroidism has been found in a significant proportion of patients on sunitinib for metastatic renal cell carcinoma or GIST and may contribute to fatigue in these patients (Chow and Eckhardt, 2007).”